Skip to main content

Axsome Therapeutics

Axsome Therapeutics, Inc. is an American commercial-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) disorders. The company focuses its operational efforts on research, clinical trials, and commercial sales of small molecule therapeutics for psychiatric and neurological conditions. Its commercial product lineup features Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness, alongside late-stage clinical pipelines for Alzheimer's agitation and migraine. Primary revenue is derived from product sales of its commercial CNS pharmaceuticals in the United States alongside licensing royalties. Axsome Therapeutics holds an established position as an innovative biopharmaceutical firm in central nervous system medicine. The company is headquartered in New York City, New York, and its shares trade on the Nasdaq Global Select Market.

10 of the funds FundTelligence covers report a position in Axsome Therapeutics.

Legal name
Axsome Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
10
Exposure themes
Depression & Mood Disorders, Mental Health, Multiple, Psychiatry, Treatment, Women's Health

Funds holding Axsome Therapeutics

Showing the 8 largest of 10 funds holding it.

Loading...